|
000
| 01925nam##2200349za#4500 |
|---|
| 001 | 9.555638 |
|---|
| 003 | CaOODSP |
|---|
| 005 | 20210615093053 |
|---|
| 007 | ta |
|---|
| 008 | 150406|2012||||xxc||||| f|0| 0 eng|d |
|---|
| 020 | |a978-0-660-67435-3 |
|---|
| 040 | |aCaOODSP|beng |
|---|
| 041 | |aeng |
|---|
| 041 | |afre |
|---|
| 043 | |an-cn--- |
|---|
| 086 | 1 |aXC62-1/411-02 |
|---|
| 110 | 1 |aCanada. |bParliament. |bHouse of Commons. |bStanding Committee on Health. |
|---|
| 245 | 10|aDrug supply in Canada : |ba multi-stakeholder responsibility / |cChair: Joy Smith, M.P. |
|---|
| 260 | |aOttawa - Ontario : |bHouse of Commons. |
|---|
| 300 | |aEnglish text, vii, 33p. : |bfigs., references ; |c28 cm. |
|---|
| 490 | 1 |aReport of the Standing Committee on Health|v41st Parliament, First Session, ninth report |
|---|
| 520 | 3 |aDuring meetings on 27 and 29 March, as well as 3 April 2012, the Committee heard from Health Canada officials, representatives of the pharmaceutical industry, healthcare professionals, pharmaceutical wholesalers and bulk purchasers, and patient advocates. This report outlines the role played by these stakeholders, summarizes the concerns that were expressed and offers recommendations that may mitigate future disruptions in the drug supply. |
|---|
| 563 | |aProcessed |
|---|
| 590 | |a12-28|b2012-07-13 |
|---|
| 690 | 07|aDrugs|2gcpds |
|---|
| 690 | 07|aPharmaceutical industry|2gcpds |
|---|
| 690 | 07|aSupply chain management|2gcpds |
|---|
| 776 | 0#|tDrug supply in Canada : |w(CaOODSP)9.574624 |
|---|
| 776 | 0#|tL'approvisionnement en médicaments au Canada : |w(CaOODSP)9.604359 |
|---|
| 792 | |tL'approvisionnement en médicaments au Canada : |w(CaOODSP)9.555639 |
|---|
| 830 | #0|aReport of the Standing Committee on Health ;|v41st Parliament, First Session, ninth report|w(CaOODSP)9.512330 |
|---|